Page last updated: 2024-08-21

pyrazines and Blood Diseases

pyrazines has been researched along with Blood Diseases in 35 studies

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (2.86)18.2507
2000's14 (40.00)29.6817
2010's19 (54.29)24.3611
2020's1 (2.86)2.80

Authors

AuthorsStudies
Ahn, IE; Cheung, J; Covey, T; Farooqui, MZH; Gaglione, EM; Gulrajani, M; Hamdy, A; Harris, HM; Herman, SEM; Izumi, R; Kendall, EK; Maric, I; Nierman, P; Patel, P; Pittaluga, S; Pleyer, C; Stetler-Stevenson, M; Sun, C; Wang, MH; Wiestner, A; Yuan, CM1
Casneuf, T; Frank, RC; Hall, B; Jagannath, S; Kranenburg, B; Krishnan, A; Lentzsch, S; Manges, RF; Orlowski, RZ; Qin, X; Somlo, G; Sonneveld, P; Thomas, SK; van de Velde, H; Voorhees, PM; Wijermans, PW; Xie, H; Zweegman, S1
Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N1
Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D1
Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS1
Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S1
Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN1
Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST1
Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M1
Ba-Mancini, A; Comenzo, RL; Duh, MS; Gravel, J; Knopf, KB; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Shi, H1
Alexeeva, J; Cavalli, F; Drach, J; Hong, X; Huang, H; Jin, J; Liu, T; Mayer, J; Okamoto, R; Osmanov, E; Pei, L; Pereira, J; Pylypenko, H; Robak, T; Rooney, B; Samoilova, O; Siritanaratkul, N; van de Velde, H; Verhoef, G; Zhu, J1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Berdel, WE; Einsele, H; Gann, CN; Knop, S; Kropff, M; Liebisch, P; Wand, H; Weisel, K1
Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P1
Gay, F; Palumbo, A1
Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W1
Alexanian, R; Delasalle, K; Giralt, S; Wang, M1
Mateos, MV1
Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S1
Blank, J; Callander, NS; Chang, JE; Choi, S; Eickhoff, JC; Gilbert, LA; Huie, MS; Kahl, BS; Kim, K; Longo, WL; McFarland, TA; Peterson, C; Rogers, ES; Volk, M; Werndli, JE; Yang, DT1
Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S1
Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF1
Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL1
Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA1
Leblond, V1
Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ1
Davies, FE; Jenner, M; Morgan, GJ; Saso, R; Srikanth, M; Wu, P1
Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH1
Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H1
Atkins, JN; Bajorin, DF; Halabi, S; Himelstein, AL; Hohl, RJ; Millard, F; Rosenberg, JE; Sanford, BL; Small, EJ1
Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H1
Alberti, D; Binger, K; Eickhoff, J; Geiger, P; Heideman, J; Kolesar, J; LoConte, NK; Marnocha, R; Thomas, JP; Utecht, K; Wilding, G1
Carey, LA; Collichio, F; Collins, J; Dees, EC; Esseltine, D; Ivanova, A; Lindley, CM; O'Neil, BH; Orlowski, RZ; Riordan, WJ1
Ames, MM; Dhodapkar, MV; Reid, JM; Richardson, RL1

Reviews

4 review(s) available for pyrazines and Blood Diseases

ArticleYear
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Hematologic Diseases; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Pneumonia; Proteasome Inhibitors; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome

2014
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis

2009
Management of treatment-related adverse events in patients with multiple myeloma.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism

2010

Trials

19 trial(s) available for pyrazines and Blood Diseases

ArticleYear
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Blood, 2020, 07-02, Volume: 136, Issue:1

    Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Enzyme Induction; Female; Headache; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Pain; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; RNA-Seq; RNA, Messenger; RNA, Neoplasm; Transcriptome; Treatment Outcome

2020
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
    British journal of haematology, 2013, Volume: 161, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; C-Reactive Protein; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infection Control; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy

2013
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2013
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
    British journal of haematology, 2014, Volume: 165, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome

2014
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
    The New England journal of medicine, 2015, Mar-05, Volume: 372, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prednisone; Pyrazines; Rituximab; Vincristine

2015
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
    Annals of hematology, 2009, Volume: 88, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Remission Induction

2009
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome

2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    British journal of haematology, 2010, Volume: 151, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia

2010
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
    British journal of haematology, 2011, Volume: 155, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Peripheral Nervous System Diseases; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Remission Induction; Rituximab; Treatment Outcome; Vincristine

2011
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    British journal of haematology, 2012, Volume: 158, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome

2012
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
    The New England journal of medicine, 2005, Jun-16, Volume: 352, Issue:24

    Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate

2005
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome

2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines

2007
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome

2008
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Transitional Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Salvage Therapy; Treatment Failure; Urologic Neoplasms

2008
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Haematologica, 2008, Volume: 93, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis

2008
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Salvage Therapy; Treatment Outcome; Ubiquitination

2008
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Treatment Outcome

2008
Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
    Investigational new drugs, 1994, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Drug Tolerance; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Pyrazines

1994

Other Studies

12 other study(ies) available for pyrazines and Blood Diseases

ArticleYear
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine

2013
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
    Annals of hematology, 2014, Volume: 93, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2014
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    American journal of hematology, 2014, Volume: 89, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome

2014
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
    Acta haematologica, 2014, Volume: 132, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome

2014
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous

2014
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide

2010
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
    Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous

2010
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
    British journal of haematology, 2012, Volume: 156, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome

2012
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome

2013
Waldenström's macroglobulinemia and bortezomib.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Diseases; Humans; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Waldenstrom Macroglobulinemia

2005
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous

2007
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
    Haematologica, 2007, Volume: 92, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome

2007